Phase 1b study of WNT inhibitor ipafricept (IPA), decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer (PC)

Colin Weeke,1 Jordan Berlin,2 Heinz-Josef Lenz,3 Bert O’Neill,4 Wells Messersmith,1 Steven J. Cohen,5 Crystal Denlinger,6 Safi Shahda,7 Ann M. Kapoun,8 Chun Zhang,9 Randall Henner,10 Fiore Cattaruzza,11 Lu Xu,12 Jakob Dupont,13 Rainer K. Brachmann,13 Shalaija Uttam singh,14 Azeez Farooqi,13 Efrafat Dotan15

1University of Colorado, Aurora, CO, USA; 2Vanderbilt University, Nashville, TN, USA; 3University of Southern California, Los Angeles, CA, USA; 4Indiana University, Indianapolis, IN, USA; 5Fox Chase Cancer Center, Philadelphia, PA, USA; 6OncoMed Pharmaceuticals, Redwood City, CA, USA; 7Memorial Sloan Kettering Cancer Center, New York, NY, USA

BACKGROUND

• To evaluate the safety and tolerability of ipafricept (IPA) in combination with Nab-P and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer (PC).

PHARMACOKINETICS AND IMMUNOGENICITY

• Ipafricept (IPA) is a recombinant human Frizzled-8 frizzled ligand antagonist.
• Ipafricept (IPA) has a half-life of 20-30 hours, and is cleared by renal/hepatic途径.

STUDY OVERVIEW

• Phase 1b study of IPA in combination with Nab-P and gemcitabine (G).

STUDY OBJECTIVES

Primary Objective

• Identification of dose-limiting toxicities (DLTs) and MTD.

Secondary Objective

• Identification of recommended Phase 2 dose (RP2D).

BASELINE CHARACTERISTICS

• Median Age: 65 years (20-76 years)
• Sex: Male (53%); Female (47%)
• Race: White (72%); Black (22%)
• ECOG Score:
  1 (22) 2 (15) 3 (3) 4 (1) 5 (1)
• Primary Tumor:
  Pancreas (72) Liver (4) Stomach (2) Others (11)

BONE SAFETY

C1: Original Safety plan based on Phase 1a

• Exclusion criteria: Vitamin D and calcium carbonate supplement.

C2-C4: Revised bone safety plan

• A total of 12 subjects had baseline CTx 1 (N=10) or CTx 2 (N=2).

EXPLORATORY EFFICACY

• MTD: 3.5 mg/kg Q2W for Cohort 1 (N=5) and 3 mg/kg Q4W for Cohort 2 (N=7).

EXPLORATORY BIOMARKERS

• 12 of 22 subjects had bone protective therapy on study.

CONCLUSIONS

• Ipafricept in combination with nab-paclitaxel and gemcitabine was well tolerated in patients with stage IV pancreatic cancer.

• Fatigue, nausea, decreased appetite, and vomiting were the most commonly reported toxicities.

ACKNOWLEDGEMENTS

• We thank all patients who participated in this study and their families. Ipafricept is part of OncoMed’s portfolio of Wnt receptor antagonists, which are believed to be novel targets for the treatment of cancer.

• All statistical analyses were performed using R statistical software (version 3.5.1).